HELX ETF — Franklin Genomic Advancements ETF

Franklin Genomic Advancements ETF (HELX)

Updated October 16, 2026.

HELX is an ETF. its distribution rate is 0.28%, its trailing-12-month yield is 0.35%, its expense ratio is 0.50%. Dividend Vision Distribution Safety Score™ is 50/100 (Unproven). Total return is 72.9% over the past 6.6 years, 109.3 points behind SPY at 182.2%.

Franklin Templeton's Franklin Genomic Advancements ETF invests at least eighty percent of its assets in equity securities of companies involved in genomic advancements, with a concentration in health care–related industries across a non-diversified portfolio. The fund does not maintain a regular distribution schedule, though it has made special distributions; it carries an expense ratio of 0.50%. This ETF may appeal to growth-oriented investors focused on the genomic and biotechnology sector rather than those seeking steady income.

HELX performance versus SPY

Price and return data through 2026-10-16.

Total return is 72.9% over the past 6.6 years, 109.3 points behind SPY at 182.2%. Over the past year its total return — price change plus distributions reinvested — is 23.6%. Its deepest 1-year drawdown was 18.0%.

HELX key facts

Distribution Safety Score™

50 · Unproven

Issuer

Franklin Templeton

Asset type

ETF

Asset class

Equity

Inception date

02/25/2020

Expense ratio

0.50%

Distribution rate

0.28%

Distribution frequency

Annual

Trailing yield

0.35%

Last close

$41.12 (as of 2026-10-16)

AUM

$29,890,376

Average volume

2069.0

Dividend

$0.143

Ex-dividend date

12/30/2025

Payment date

01/08/2026

Beta

0.93

How Dividend Vision calculates yield and returns

Distribution rate (0.28%) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield (0.35%) is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: Franklin Templeton; prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

HELX risks and drawbacks

HELX's current distribution rate is moderate, not a high-yield payout — the strategy is dividend quality more than maximum income. Payments are annual, so cash flow is lumpy versus a monthly fund. Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 18.0%.

Who may consider HELX — and who may not

It is a weaker fit for investors who need monthly cash flow (HELX pays annual); investors hunting double-digit covered-call yields; investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on HELX

• All tickers starting with H

Frequently asked questions

More securities from Franklin Templeton.